DNA RNA and Cells
4 September 2024
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA4 September 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs Through Clinical Development3 September 2024
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-153 September 2024
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect22 August 2024
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World’s First In Vivo Gene Editing Therapy for PH122 August 2024
Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding22 August 2024
ImmPACT Bio Announces FDA Clearance of IND Application for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis21 August 2024
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome15 August 2024
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease15 August 2024
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer15 August 2024
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical StudiesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports